Parkwood LLC Invests $10.75 Million in Baxter International Inc. (NYSE:BAX)

Parkwood LLC acquired a new position in Baxter International Inc. (NYSE:BAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 368,560 shares of the medical instruments supplier's stock, valued at approximately $10,747,000. Baxter International makes up 1.2% of Parkwood LLC's holdings, making the stock its 29th largest holding. Parkwood LLC owned approximately 0.07% of Baxter International at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Dodge & Cox grew its holdings in shares of Baxter International by 13.0% in the 4th quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier's stock worth $1,469,002,000 after acquiring an additional 5,779,100 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Baxter International by 22.3% during the fourth quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier's stock worth $447,870,000 after purchasing an additional 2,803,920 shares during the period. Geode Capital Management LLC raised its position in shares of Baxter International by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 12,446,939 shares of the medical instruments supplier's stock worth $362,006,000 after purchasing an additional 290,279 shares during the period. Thompson Siegel & Walmsley LLC raised its position in shares of Baxter International by 35.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 2,548,215 shares of the medical instruments supplier's stock worth $74,306,000 after purchasing an additional 662,042 shares during the period. Finally, Sound Shore Management Inc. CT acquired a new stake in shares of Baxter International during the fourth quarter worth $72,450,000. Institutional investors own 90.19% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Barclays boosted their target price on Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Monday, March 10th. Argus upgraded Baxter International from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Morgan Stanley lowered their price target on Baxter International from $30.00 to $28.00 and set an "underweight" rating on the stock in a report on Monday, May 5th. The Goldman Sachs Group initiated coverage on Baxter International in a report on Wednesday, February 26th. They set a "buy" rating and a $42.00 price target on the stock. Finally, Wells Fargo & Company lowered their price target on Baxter International from $36.00 to $33.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $37.25.

Baxter International Stock Down 0.2%

BAX stock traded down $0.07 during mid-day trading on Monday, hitting $31.60. The stock had a trading volume of 1,024,118 shares, compared to its average volume of 4,509,461. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a 1-year low of $26.25 and a 1-year high of $40.49. The company has a fifty day moving average of $31.16 and a 200 day moving average of $31.78. The stock has a market capitalization of $16.21 billion, a price-to-earnings ratio of -24.63, a PEG ratio of 0.93 and a beta of 0.63.

Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.14. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The company had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same period in the prior year, the firm posted $0.65 EPS. The business's revenue was up 5.4% compared to the same quarter last year. On average, equities analysts expect that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Stockholders of record on Friday, May 30th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.68 annualized dividend and a dividend yield of 2.15%. Baxter International's dividend payout ratio (DPR) is presently -61.82%.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.